Guardant Health, Inc. (NASDAQ:GH) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

Guardant Health, Inc. (NASDAQ:GH) has earned an average recommendation of “Moderate Buy” from the twenty-four analysts that are currently covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation and twenty-three have assigned a buy recommendation to the company. The average 12-month price target among brokers that have covered the stock in the last year is $96.7143.

GH has been the topic of several research reports. Leerink Partners raised their target price on Guardant Health from $115.00 to $155.00 and gave the stock an “outperform” rating in a research report on Monday, December 15th. Morgan Stanley raised their price objective on shares of Guardant Health from $105.00 to $130.00 and gave the stock an “overweight” rating in a report on Monday, December 1st. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Guardant Health in a report on Wednesday, October 8th. UBS Group increased their price target on shares of Guardant Health from $80.00 to $110.00 and gave the stock a “buy” rating in a research report on Thursday, October 30th. Finally, Canaccord Genuity Group boosted their price objective on shares of Guardant Health from $100.00 to $125.00 and gave the company a “buy” rating in a research report on Monday.

Insider Buying and Selling at Guardant Health

In related news, CEO Helmy Eltoukhy sold 90,565 shares of the business’s stock in a transaction that occurred on Monday, December 15th. The stock was sold at an average price of $103.82, for a total transaction of $9,402,458.30. Following the completion of the transaction, the chief executive officer directly owned 2,047,143 shares in the company, valued at approximately $212,534,386.26. The trade was a 4.24% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Medina Manuel Hidalgo sold 1,250 shares of the firm’s stock in a transaction that occurred on Monday, December 8th. The stock was sold at an average price of $105.00, for a total transaction of $131,250.00. Following the sale, the director owned 797 shares in the company, valued at approximately $83,685. The trade was a 61.06% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 426,663 shares of company stock valued at $44,508,069 in the last ninety days. 6.10% of the stock is currently owned by company insiders.

Institutional Trading of Guardant Health

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Signaturefd LLC lifted its stake in shares of Guardant Health by 50.5% during the 2nd quarter. Signaturefd LLC now owns 635 shares of the company’s stock valued at $33,000 after buying an additional 213 shares in the last quarter. IFP Advisors Inc lifted its position in shares of Guardant Health by 120.1% in the second quarter. IFP Advisors Inc now owns 612 shares of the company’s stock valued at $33,000 after acquiring an additional 334 shares in the last quarter. Allworth Financial LP lifted its position in shares of Guardant Health by 358.4% in the second quarter. Allworth Financial LP now owns 706 shares of the company’s stock valued at $37,000 after acquiring an additional 552 shares in the last quarter. Sound Income Strategies LLC bought a new position in shares of Guardant Health in the third quarter worth about $38,000. Finally, Optiver Holding B.V. grew its position in shares of Guardant Health by 153.5% during the third quarter. Optiver Holding B.V. now owns 768 shares of the company’s stock worth $48,000 after purchasing an additional 465 shares in the last quarter. 92.60% of the stock is owned by hedge funds and other institutional investors.

Guardant Health Trading Up 0.1%

Shares of GH stock opened at $102.59 on Friday. Guardant Health has a 12-month low of $29.91 and a 12-month high of $112.43. The stock has a market capitalization of $12.93 billion, a P/E ratio of -31.96 and a beta of 1.58. The firm’s 50 day moving average is $95.28 and its 200 day moving average is $68.92.

Guardant Health (NASDAQ:GH) last released its quarterly earnings results on Wednesday, October 29th. The company reported ($0.39) earnings per share for the quarter, beating the consensus estimate of ($0.48) by $0.09. During the same period in the prior year, the firm earned ($0.88) EPS. The business’s quarterly revenue was up 38.5% compared to the same quarter last year. As a group, equities analysts predict that Guardant Health will post -2.9 earnings per share for the current year.

Guardant Health Company Profile

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.